AbbVie Aktie
| 167,35USD | -0,37USD | -0,22% |
WKN DE: A1J84E / ISIN: US00287Y1091
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,91 |
| Vanguard Group, Inc. (Subfiler) | 9,25 |
| The Vanguard Group, Inc. | 9,08 |
| State Street Corp. | 4,48 |
| Vanguard Total Stock Market ETF | 3,17 |
| BlackRock Fund Advisors | 2,87 |
| Vanguard 500 Index Fund | 2,62 |
| BlackRock Institutional Trust Co. NA | 2,18 |
| Capital Research & Management Co. (International Investors) | 2,08 |
| Geode Capital Management LLC | 2,05 |
| Capital Research & Management Co. (Global Investors) | 1,88 |
| JPMorgan Investment Management, Inc. | 1,84 |
| Charles Schwab Investment Management, Inc. | 1,35 |
| Norges Bank (13F) | 1,27 |
| Morgan Stanley Smith Barney LLC | 1,24 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 30 000 | 47 000 | 50 000 | 50 000 | 50 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,11 | 0,97 | 1,12 | 1,16 | 1,09 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 49 519 | 24 173 | 27 928 | 28 463 | 33 002 |
| Summe Anlagevermögen | 39 596 | 126 392 | 118 601 | 110 342 | 101 709 |
| Summe Aktiva | 89 115 | 150 565 | 146 529 | 138 805 | 134 711 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 67 088 | 87 063 | 77 575 | 64 191 | 60 120 |
| Summe Fremdkapital | 97 287 | 137 468 | 131 093 | 121 518 | 124 314 |
| Summe Eigenkapital | -8 172 | 13 097 | 15 436 | 17 287 | 10 397 |
| Summe Passiva | 89 115 | 150 565 | 146 529 | 138 805 | 134 711 |
Adresse
| 1 North Waukegan Road, 60064-6400 North Chicago | |
| Telefon | +1 (847) 932-7900 |
| Internet | http://www.abbvie.com |
Management
|
Azita Saleki-Gerhardt
Co-Chief Operations Officer & Executive VP |
|
Brett J. Hart
Independent Director |
|
Brian L. Durkin
Vice President |
|
Carrie Strom
Senior VP & President-Global Allergan Aesthetics |
|
Edward J. Rapp
Independent Director |
|
Esteban Plata
Vice President-Western Europe & Canada |
|
Frederick H. Waddell
Independent Director |
|
Glenn Fletcher Tilton
Independent Director |
|
Jennifer L. Davis
Independent Director |
|
Kevin K. Buckbee
Senior Vice President & Controller |
|
Liz Shea
Head-Investor Relations |
|
Melody B. Meyer
Independent Non-Executive Director |
|
Nicholas Donoghoe
Chief Business & Strategy Officer |
|
Perry C. Siatis
Secretary, Executive VP & General Counsel |
|
Rebecca Brown Roberts
Independent Director |
|
Richard A. Gonzalez
Executive Chairman |
|
Robert A. Michael
Chief Executive Officer & Director |
|
Robert J. Alpern
Independent Director |
|
Roopal Thakkar
Chief Scientific Officer, Executive VP-R&D |
|
Roxanne Schuh Austin
Lead Independent Director |
|
Scott T. Reents
Chief Financial Officer & Executive Vice President |
|
Susan E. Quaggin
Independent Director |
|
Thomas C. Freyman
Independent Director |
|
Timothy J. Richmond
Chief Human Resources Officer & Executive VP |
|
Todd D. Bosse
Vice President-Investor Relations |
|
William H. L. Burnside
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
